Drugs / abnobaVISCUM 900
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02106572 | Apr 2015 → Mar 2026 | superficial urinary bladder carcinoma | Abnoba GmbH | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | abnobaVISCUM 900 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02106572 ↗ |
| Route | Other | “intravesical instillation of abnobaVISCUM 900” NCT02106572 ↗ |